Imatinib (Gleevec) has become a paradigm for targeted cancer therapies. Although the majority of patients with chronic myeloid leukemia (CML) respond well to imatinib, a minority of patients have relapsed. This part of the lecture will cover what has been learned about mechanisms of relapse and how this information has been translated into new therapies for patients with imatinib resistance. Although imatinib is a relatively specific inhibitor of the ABL kinase, a couple of other kinases, KIT and the platelet derived growth factor receptor are also inhibited by imatinib. This use of this information to treat successfully treat other malignant diseases driven by these kinases will be reviewed. See more at www.ibioseminars.org
Tags: imatinib, gleevec, chronic myeloid leukemia, CML, leukemia, Bcr-Abl, Abl-kinase, oncogene, imatinib resistance, kinase inhibitor, kinase mutation, nilotinib, dasatinib
No comments:
Post a Comment